| Targeting cytokine-and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma R De Smedt, J Morscio, L Reunes, J Roels, V Bardelli, B Lintermans, ... Blood, The Journal of the American Society of Hematology 135 (19), 1685-1695, 2020 | 30 | 2020 |
| Targeting steroid resistance in T-cell acute lymphoblastic leukemia R De Smedt, J Morscio, S Goossens, P Van Vlierberghe Blood reviews 38, 100591, 2019 | 27 | 2019 |
| Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma R De Smedt, S Peirs, J Morscio, F Matthijssens, J Roels, L Reunes, ... Haematologica 104 (1), e17, 2019 | 22 | 2019 |
| Pre-clinical evaluation of the hypomethylating agent decitabine for the treatment of T-cell lymphoblastic lymphoma L Provez, T Putteman, M Landfors, J Roels, L Reunes, S T’Sas, ... Cancers 15 (3), 647, 2023 | 2 | 2023 |
| Direct and indirect anti-leukemic properties of activity-on-target interferons for the treatment of T-cell acute lymphoblastic leukemia S Goossens, A Cauwels, T Pieters, R De Smedt, S T’Sas, A Almeida, ... Haematologica 107 (6), 1448, 2022 | 2 | 2022 |
| Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma S De Coninck, R De Smedt, B Lintermans, L Reunes, HJ Kosasih, ... Haematologica 109 (5), 1373, 2024 | 1 | 2024 |
| PDGFR-β As a New Therapeutic Target in T-Cell Acute Lymphoblastic Leukemia S De Coninck, R De Smedt, B Lintermans, S Goossens, ... Blood 140 (Supplement 1), 11513-11514, 2022 | 1 | 2022 |
| P317: TARGETING HYPERACTIVE PDGFR-B IN T-ALL AND T-LBL S De Coninck, P Van Vlierberghe, S Goossens, R De Smedt, ... HemaSphere 6, 217-218, 2022 | | 2022 |
| 3066–TARGETING HYPERACTIVE PLATELET DERIVED GROWTH FACTOR RECEPTOR BETA IN T CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T CELL LYMPHOBLASTIC LYMPHOMA S De Coninck, R De Smedt, B Lintermans, S Goossens, ... Experimental Hematology 111, S77-S78, 2022 | | 2022 |
| Finding the'key'in leukemia: PIM1 inhibition as a novel therapy in T-cell acute lymphoblastic leukemia R De Smedt Ghent University, 2020 | | 2020 |
| Targeting cytokine and therapy induced PIM1 activation in T-cell acute lymphoblastic leukemia and lymphoma. B De Moerloose, R De Smedt, J Morscio, L Reunes, J Roels, V Bardelli, ... BLOOD, 2020 | | 2020 |
| PF157 THERAPEUTIC TARGETING OF CYTOKINE INDUCED PIM1 ACTIVATION IN T‐CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOMA R De Smedt, S Peirs, M Van Trimpont, J Morscio, J Roels, L Reunes, ... HemaSphere 3, 30, 2019 | | 2019 |
| Genetic Activation and Therapeutic Targeting of PIM1 in T-Cell Acute Lymphoblastic Leukemia/Lymphoma R De Smedt, S Peirs, J Morscio, J Roels, S Goossens, A Touzart, ... Blood, The Journal of the American Society of Hematology 130 (Suppl_1), 1445 …, 2017 | | 2017 |
| GENETIC ACTIVATION AND THERAPEUTIC TARGETING OF PIM1 IN T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA R De Smedt, S Peirs, J Morscio, J Roels, S Goossens, A Touzart, ... Haematologica 102, 28-28, 2017 | | 2017 |
| P153 E Vroegindeweij, R De Smedt, K Canté-Barrett, E Splinter, A Uyttebroeck, ... | | 2016 |
| Identification of candidate oncogenes and chromosomal breakpoint sequencing by targeted locus amplification in T-cell acute lymphoblastic leukemia B De Moerloose, E Vroegindeweij, T Lammens, K Canté-Barett, E Splinter, ... | | 2016 |
| Identification of candidate oncogenes and chromosomal breakpoint sequencing by targeted locus amplification in T-cell acute lymphoblastic leukemia E Vroegindeweij, T Lammens, K Cante-Barrett, E Splinter, A Uyttebroeck, ... 21st Congress of the European Hematology Association 101 (suppl. 1), 26-26, 2016 | | 2016 |
| De rol van PHF6 in acute T‐cel leukemie R De Smedt | | |
